Fruquintinib

Drug Profile

Fruquintinib

Alternative Names: HMPL-013

Latest Information Update: 06 Dec 2016

Price : $50

At a glance

  • Originator Hutchison MediPharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Colorectal cancer; Non-small cell lung cancer
  • Phase II Solid tumours
  • Phase I Gastric cancer

Most Recent Events

  • 29 Nov 2016 Efficacy and adverse events data from a phase II trial in Non-small cell lung cancer released by Hutchison Medipharma
  • 01 Sep 2016 Hutchison Medipharma Limited completes a a phase I pharmacokinetics trial in Healthy volunteers in China (PO) (NCT02689752)
  • 02 Aug 2016 Hutchison MediPharma announces intention to submit NDA in China for Colorectal cancer (in mid-2017) and Non-small cell lung cancer (in 1H 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top